Optimal asthma control, starting with high doses of inhaled budesonide

The aim of this study was to determine whether outcomes in poorly controlled asthma can be further improved with a starting dose of inhaled budesonide higher than that recommended in international guidelines. The study had a parallel-group design and included 61 subjects with poorly controlled asthma, randomized to receive 3,200 microg or 1,600 microg budesonide daily by Turbuhaler for 8 weeks (double-blind), then 1,600 microg x day(-1) for 8 weeks (single-blind), followed by 14 months of open-label budesonide dose down-titration using a novel algorithm, with a written asthma crisis plan based on electronic peak expiratory flow monitoring. The primary outcome variable for weeks 1-16 was change in airway hyperresponsiveness (AHR), and, for the open-label phase, mean daily budesonide dose. By week 16, there were large changes from baseline in all outcomes, with no significant differences between the 3,200- and 1,600-microg x day(-1) starting dose groups (AHR increased by 3.2 versus 3.0 doubling doses, p=0.7; morning peak flow increased by 134 versus 127 L x min(-1), p=0.8). Subjects starting with 3,200 microg x day(-1) were 3.8 times more likely to achieve AHR within the normal range, as defined by a provocative dose of histamine causing a 20% fall in forced expiratory volume in one second (PD20) of > or = 3.92 micromol by week 16 (p=0.03) [corrected]. During dose titration, there was no significant difference in mean budesonide dose (1,327 versus 1,325 microg x day(-1), p>0.3). Optimal asthma control was achieved in the majority of subjects (at completion/withdrawal: median symptoms 0.0 days x week(-1), beta2-agonist use 0.2 occasions x day(-1), and PD20 2.4 micromol). In subjects with poorly controlled asthma, a starting dose of 1,600 microg x day(-1) budesonide was sufficient to lead to optimal control in most subjects. The high degree of control achieved, compared with previous studies, warrants further investigation.

This article has been cited by other articles:

				M. Gaga, E. Zervas, and P. Chanez Update on severe asthma: what we know and what we need Eur. Respir. Rev., June 1, 2009; 18(112): 58 - 65. [Full Text] [PDF]

				P. M. O'Byrne, I. P. Naya, A. Kallen, D. S. Postma, and P. J. Barnes Increasing Doses of Inhaled Corticosteroids Compared to Adding Long-Acting Inhaled {beta}2-Agonists in Achieving Asthma Control Chest, December 1, 2008; 134(6): 1192 - 1199. [Abstract] [Full Text] [PDF]

				D. R. Taylor, E. D. Bateman, L-P. Boulet, H. A. Boushey, W. W. Busse, T. B. Casale, P. Chanez, P. L. Enright, P. G. Gibson, J. C. de Jongste, et al. A new perspective on concepts of asthma severity and control Eur. Respir. J., September 1, 2008; 32(3): 545 - 554. [Abstract] [Full Text] [PDF]

				E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S. E. Pedersen, et al. Global strategy for asthma management and prevention: GINA executive summary Eur. Respir. J., January 1, 2008; 31(1): 143 - 178. [Abstract] [Full Text] [PDF]

				A. L. James and S. Wenzel Clinical relevance of airway remodelling in airway diseases Eur. Respir. J., July 1, 2007; 30(1): 134 - 155. [Abstract] [Full Text] [PDF]

				S. O Shaheen, R. B Newson, M. P Rayman, A. P-L Wong, M. K Tumilty, J. M Phillips, J. F Potts, F. J Kelly, P. T White, and P. G J Burney Randomised, double blind, placebo-controlled trial of selenium supplementation in adult asthma Thorax, June 1, 2007; 62(6): 483 - 490. [Abstract] [Full Text] [PDF]

				C. Vogelmeier, A. D'Urzo, R. Pauwels{dagger}, J. M. Merino, M. Jaspal, S. Boutet, I. Naya, and D. Price Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur. Respir. J., November 1, 2005; 26(5): 819 - 828. [Abstract] [Full Text] [PDF]

				C. R. Jenkins, F. C. K. Thien, J. R. Wheatley, and H. K. Reddel Traditional and patient-centred outcomes with three classes of asthma medication Eur. Respir. J., July 1, 2005; 26(1): 36 - 44. [Abstract] [Full Text] [PDF]

				G. P. Currie and D. K. C. Lee The GOAL Study Designed to Favor a Long-acting {beta}2-Agonist? Am. J. Respir. Crit. Care Med., May 1, 2005; 171(9): 1060 - 1061. [Full Text] [PDF]

				H.K. Reddel Goals of asthma treatment: how high should we go? Eur. Respir. J., November 1, 2004; 24(5): 715 - 717. [Full Text] [PDF]

				F. Thien Review: adults who require inhaled corticosteroids benefit from a moderate starting dose Evid. Based Med., November 1, 2004; 9(6): 178 - 178. [Full Text] [PDF]

				H K Reddel, G B Marks, and C R Jenkins When can personal best peak flow be determined for asthma action plans? Thorax, November 1, 2004; 59(11): 922 - 924. [Abstract] [Full Text] [PDF]

				E. D. Bateman, H. A. Boushey, J. Bousquet, W. W. Busse, T. J. H. Clark, R. A. Pauwels, S. E. Pedersen, and for the GOAL Investigators Group Can Guideline-defined Asthma Control Be Achieved?: The Gaining Optimal Asthma ControL Study Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 836 - 844. [Abstract] [Full Text] [PDF]

				M. Masoli, M. Weatherall, S. Holt, and R. Beasley From the authors: Eur. Respir. J., September 1, 2004; 24(3): 513 - 514. [Full Text] [PDF]

				M. Masoli, S. Holt, M. Weatherall, and R. Beasley Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis Eur. Respir. J., April 1, 2004; 23(4): 552 - 558. [Abstract] [Full Text] [PDF]

				J. I Peters Inhaled corticosteroids were safely stepped down in chronic, stable asthma Evid. Based Med., January 1, 2004; 9(1): 16 - 16. [Full Text] [PDF]

				C M Salome, J D Leuppi, R Freed, and G B Marks Perception of airway narrowing during reduction of inhaled corticosteroids and asthma exacerbation Thorax, December 1, 2003; 58(12): 1042 - 1047. [Abstract] [Full Text] [PDF]

				S.T. Holgate, D. E. Davies, S. Puddicombe, A. Richter, P. Lackie, J. Lordan, and P. Howarth Mechanisms of airway epithelial damage: epithelial-mesenchymal interactions in the pathogenesis of asthma Eur. Respir. J., September 20, 2003; 22(44_suppl): 24s - 29s. [Full Text] [PDF]

				D B Price, D Hernandez, P Magyar, J Fiterman, K M Beeh, I G James, S Konstantopoulos, R Rojas, J A van Noord, M Pons, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma Thorax, March 1, 2003; 58(3): 211 - 216. [Abstract] [Full Text] [PDF]

				A. L. James, P. S. Maxwell, G. Pearce-Pinto, J. G. Elliot, and N. G. Carroll The Relationship of Reticular Basement Membrane Thickness to Airway Wall Remodeling in Asthma Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): 1590 - 1595. [Abstract] [Full Text] [PDF]

				J-M. Ignacio-Garcia, M. Pinto-Tenorio, M.J. Chocron-Giraldez, F. Cabello-Rueda, A.I. Lopez-Cozar Gil, J-M. Ignacio-Garcia, and E. de Ramon-Garrido Benefits at 3 yrs of an asthma education programme coupled with regular reinforcement Eur. Respir. J., November 1, 2002; 20(5): 1095 - 1101. [Abstract] [Full Text] [PDF]

				H K Reddel, G B Marks, C M Salome, C R Jenkins, C Ward, D Reid, and E H Walters Inhaled corticosteroid dosage in asthma Thorax, September 1, 2002; 57(9): 837 - 838. [Full Text]

				H. K Reddel, B. G Toelle, G. B Marks, S. I Ware, C. R Jenkins, and A. J Woolcock Analysis of adherence to peak flow monitoring when recording of data is electronic BMJ, January 19, 2002; 324(7330): 146 - 147. [Full Text] [PDF]

				C. M. SALOME, H. K. REDDEL, S. I. WARE, A. M. ROBERTS, C. R. JENKINS, G. B. MARKS, and A. J. WOOLCOCK Effect of Budesonide on the Perception of Induced Airway Narrowing in Subjects with Asthma Am. J. Respir. Crit. Care Med., January 1, 2002; 165(1): 15 - 21. [Abstract] [Full Text] [PDF]

				M. J. VISSER, D. S. POSTMA, L. R. ARENDS, T. W. DE VRIES, E. J. DUIVERMAN, and P. L. P. BRAND One-Year Treatment with Different Dosing Schedules of Fluticasone Propionate in Childhood Asthma . Effects on Hyperresponsiveness, Lung Function, and Height Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2073 - 2077. [Abstract] [Full Text] [PDF]

				B. J. Lipworth, S. Edsbacker, L. P. Nielsen, and R. Dahl THE PROBLEM OF DOSE-RESPONSE AND THERAPEUTIC RATIO OF INHALED STEROIDS Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1758 - 1759. [Full Text] [PDF]

				S. T. Holgate Therapeutic Options for Persistent Asthma JAMA, May 23, 2001; 285(20): 2637 - 2639. [Full Text] [PDF]

				E.D. Bateman, J. Bousquet, and G.L. Braunstein Is overall asthma control being achieved? A hypothesis-generating study Eur. Respir. J., April 1, 2001; 17(4): 589 - 595. [Abstract] [Full Text] [PDF]